Nature Communications, Published online: 13 June 2026; doi:10.1038/s41467-026-73931-2 Bone metastases derived from lung cancer typically exhibit an immunosuppressive microenvironment. This study identifies a YBX1 glycosylation–dependent mechanism that drives both metastasis and immunosuppression, and proposes the small molecule Icaritin as a potential therapeutic strategy through YBX1 degradation.